Aslan Pharmaceuticals Stock Return On Equity
| ASLNDelisted Stock | USD 0.60 0.03 4.76% |
Aslan Pharmaceuticals fundamentals help investors to digest information that contributes to Aslan Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aslan Stock. The fundamental analysis module provides a way to measure Aslan Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aslan Pharmaceuticals stock.
Aslan |
Aslan Pharmaceuticals Company Return On Equity Analysis
Aslan Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Aslan Pharmaceuticals Return On Equity | -4.27 |
Most of Aslan Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aslan Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Aslan Pharmaceuticals has a Return On Equity of -4.2664. This is 82.2% lower than that of the Biotechnology sector and 88.3% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Aslan Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aslan Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics of similar companies.Aslan Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Aslan Fundamentals
| Return On Equity | -4.27 | |||
| Return On Asset | -0.54 | |||
| Profit Margin | (2.92) % | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 288.33 M | |||
| Shares Outstanding | 2.83 M | |||
| Shares Owned By Insiders | 0.14 % | |||
| Shares Owned By Institutions | 13.21 % | |||
| Number Of Shares Shorted | 306.56 K | |||
| Price To Earning | (11.50) X | |||
| Price To Book | 2.14 X | |||
| Price To Sales | 0.94 X | |||
| Revenue | 12 M | |||
| Gross Profit | 79.82 M | |||
| EBITDA | (43.39 M) | |||
| Net Income | (44.22 M) | |||
| Cash And Equivalents | 78.12 M | |||
| Cash Per Share | 1.12 X | |||
| Total Debt | 26.83 M | |||
| Debt To Equity | 1.12 % | |||
| Current Ratio | 6.97 X | |||
| Book Value Per Share | (7.70) X | |||
| Cash Flow From Operations | (46.36 M) | |||
| Short Ratio | 1.85 X | |||
| Earnings Per Share | (16.00) X | |||
| Target Price | 72.0 | |||
| Number Of Employees | 35 | |||
| Beta | 1.4 | |||
| Market Capitalization | 1.7 M | |||
| Total Asset | 24.63 M | |||
| Retained Earnings | (321.07 M) | |||
| Working Capital | 11.02 M | |||
| Current Asset | 54.61 M | |||
| Current Liabilities | 5.15 M | |||
| Net Asset | 24.63 M |
About Aslan Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aslan Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aslan Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Aslan Stock
Moving against Aslan Stock
| 0.89 | WMT | Walmart Aggressive Push | PairCorr |
| 0.83 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.76 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.76 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
| 0.75 | CSCO | Cisco Systems Aggressive Push | PairCorr |
The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals to buy it.
The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |